📰 Single Dose Study News
Single Dose Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Single Dose Study. Real-time updates on events, politics, business and more.
October 16, 2023
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-sourced...
June 26, 2023
Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.
June 25, 2023
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2023--
June 25, 2023
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2023--
March 30, 2023
~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech
March 30, 2023
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial ...
December 11, 2020
Celltrion Healthcare receives EU CHMP positive opinion for biosimilar adalimumab, CT-P17 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of CT-P17 (adalimumab biosimilar) for the treatment of multiple chronic inflammatory diseases The positive opinion is based on Phase I/III study data investigating the equivalence of CT-P17 to reference adalimumab in terms of efficacy, pharmacokinetics (PK) and overall safety If ap...